摘要
目的比较替吉奥与卡培他滨分别联合奥沙利铂治疗结直肠癌的疗效和安全性。方法将76例结直肠癌患者随机分为A组(36例)和B组(40例),A组第1天静脉滴注奥沙利铂,同时口服替吉奥14 d; B组第1天静脉滴注奥沙利铂,同时口服卡培他滨14 d。2个化疗周期后计算客观缓解率(ORR)、疾病控制率(DCR)和不良反应发生率。结果两组的ORR及DCR均无统计学差异(33.33%比40.00%,69.44%比72.50%,P> 0.05);但A组的血小板减少、肾功能异常、手足综合征的发生率明显低于B组(P <0.05),其余不良反应发生率无明显差异(P> 0.05)。结论两组方案均能有效治疗结肠癌,且疗效无明显差异,但替吉奥联合奥沙利铂安全性更高,为临床较优选择。
Objective To compare the clinical effect and safety of oxaliplatin combined with tegafur,gimeracil and oteracil potassium(S-1)or capecitabine in the treatment of colorectal cancer.Methods Totally 76 patients with colorectal cancer were randomly divided into group A(36 cases) and group B(40 cases).The patients in group A were given intravenous drip of oxaliplatin on the first day, and took S-1 orally for 14 days.The patients in group B were given intravenous drip of oxaliplatin on the first day,and took capecitabine orally for 14 days.After 2 cycles of chemotherapy,the objective remission rate(ORR),disease control rate(DCR) and the incidence rate of adverse reaction were calculated.Results There was no significant difference in ORR and DCR between the two groups(33.33%vs.40.00%,69.44% vs.72.50%, P > 0.05).The incidence rates of thrombocytopenia,renal dysfunction and hand-foot syndrome in group A were significantly lower than those in group B(P < 0.05), but there was no significant difference in the incidence rate of other adverse reactions between the two groups(P > 0.05).Conclusion Both of the two regimens can effectively treat colon cancer,and there is no significant difference in curative effect,but S-1 combined with oxaliplatin is safer,which is a better choice in clinic.
作者
张伶俐
谢学建
高茗
王锐
宋海珠
宋小骏
王楠
ZHANG Lingli;XIE Xuejian;GAO Ming;WANG Rui;SONG Haizhu;SONG Xiaojun;WANG Nan(General Hospital of Eastern Theater Command of PLA, Nanjing, Jiangsu, China 210002)
出处
《中国药业》
CAS
2019年第7期60-62,共3页
China Pharmaceuticals
基金
南京药学会-常州四药医院药学科研基金项目[2015YX012]
关键词
替吉奥
卡培他滨
结直肠癌
奥沙利铂
疗效
药品不良反应
tegafur,gimeracil and oteracil potassium
capecitabine
colorectal cancer
oxaliplatin
curative effect
adverse drug reaction
